Targeted Radiotherapies for Unmet Needs
Actinium Pharmaceuticals, Inc. (actiniumpharma.com) scores 70 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, in the 24th percentile of 19552 Healthcare brands.
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company that develops targeted radiotherapies for cancer and other serious diseases. Using proprietary Actinium-225 manufacturing technology and targeted conditioning platforms, the company is advancing a pipeline that includes Actimab-A and ATNM-400, aimed at difficult-to-treat cancers such as AML, mCRPC, NSCLC, and breast cancer. Its work targets oncologists, biopharmaceutical partners, investors, and patients with hematologic and solid tumor cancers.
| Brand Name | Actinium Pharmaceuticals, Inc. |
|---|---|
| Domain | actiniumpharma.com |
| Industry | Healthcare |
| Main Competitors | Novartis (Advanced Accelerator Applications) (75/100), Fusion Pharmaceuticals (76/100), Telix Pharmaceuticals (75/100), Lantheus Holdings (80/100), POINT Biopharma (70/100), RayzeBio (76/100), Bayer (Radiopharmaceuticals) (76/100), Orano Med (70/100) |
Moz Domain Authority 40/100 vs category average 40 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #2,382,449 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Actinium Pharmaceuticals develops targeted radiotherapies to address unmet needs for patients with cancer and other serious diseases." (No meta description) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:image, og:type. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Apache.
Social footprint: verified profiles on X (Twitter), Facebook, Instagram, YouTube; no detected presence on LinkedIn, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Actinium Pharmaceuticals, Inc.?", Claude could identify the brand as of October 2026. Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for cancer and other serious diseases, using antibody radiation conjugates like Iomab-B and Actimab-A primarily in blood cancers and bone marrow transplant conditi Best known for Developing Iomab-B, a targeted radiotherapy used to condition patients for bone marrow transplants in relapsed/refractory AML.
When asked "Best brands similar to Actinium Pharmaceuticals, Inc.?", Claude would recommend Actinium Pharmaceuticals, Inc. as of October 2026. It's a recognizable name in the targeted radiotherapy and antibody-drug conjugate space for oncology, so it would come up in discussions of companies pioneering radioimmunotherapy for blood cancers.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Actinium Pharmaceuticals, Inc.'s main competitors in Healthcare: Novartis (Advanced Accelerator Applications) (75/100), Fusion Pharmaceuticals (76/100), Telix Pharmaceuticals (75/100), Lantheus Holdings (80/100), POINT Biopharma (70/100).
Sources: Brand Analyzer scan
Actinium Pharmaceuticals offers a pipeline of targeted radiotherapy product candidates, including Actimab-A and ATNM-400, developed using its proprietary Actinium-225 manufacturing technology and targeted conditioning platforms. These therapies are being developed for hematologic and solid tumor cancers such as AML, mCRPC, NSCLC, and breast cancer.
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing targeted radiotherapies to treat cancer and other serious diseases.
Actinium Pharmaceuticals, Inc. has low AI-search visibility, scoring 20/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 29, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Actinium Pharmaceuticals, Inc. scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Actinium Pharmaceuticals is known for its proprietary Actinium-225 isotope manufacturing technology and for developing targeted radiotherapy candidates like Actimab-A and ATNM-400 aimed at hard-to-treat cancers such as AML, mCRPC, NSCLC, and breast cancer.
Actinium Pharmaceuticals, Inc. can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Actinium Pharmaceuticals' work is relevant to oncologists, biopharmaceutical partners, investors, and patients with hematologic and solid tumor cancers such as AML, mCRPC, NSCLC, and breast cancer.
Actinium Pharmaceuticals, Inc. scores 20/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Actinium Pharmaceuticals, Inc. has a weak AI-visibility profile at 20/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (0/100). It benefits from a global traffic rank of #2,382,449 (Tranco), a Moz Domain Authority of 40/100 and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and thin schema.org structured data. In a live check, Claude could already identify Actinium Pharmaceuticals, Inc. from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Actinium Pharmaceuticals, Inc.: UniMed (formerly Accuro) (70/100), AccessEAP (70/100), Adherium (70/100), Adirondack Health (70/100).
A step up - brands to learn from: Zentralwohlfahrtsstelle der Juden in Deutschland e.V. (71/100), ZT Corporate (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.